Bioelectronics Corp (BIEL)

[ddls]

The FDA studies were fixed and flawed. Also, BioElectronics didn't come close to winning the FDA Opioid Challenge. The device barely squeaked by the fixed and flawed studies.

The FDA should have saved BIEL'S investors the pain and cleared it in 2008-9 since the device is totally worthless like ActiBand was.

But, with that said, consumers will find out soon enough the device is useless 95% of the time.

Declining Sales Cheers!